APG Asset Management N.V. raised its stake in shares of Gilead Sciences Inc. (NASDAQ:GILD) by 30.0% during the third quarter, according to its most recent 13F filing with the SEC. The fund owned 4,848,185 shares of the biopharmaceutical company’s stock after buying an additional 1,119,000 shares during the period. Gilead Sciences accounts for 0.7% of APG Asset Management N.V.’s portfolio, making the stock its 28th largest position. APG Asset Management N.V. owned approximately 0.37% of Gilead Sciences worth $383,588,000 at the end of the most recent quarter.
Several other large investors have also added to or reduced their stakes in the stock. Bank of Montreal Can acquired a new stake in Gilead Sciences during the second quarter valued at approximately $427,750,000. Capital World Investors boosted its stake in Gilead Sciences by 28.3% in the second quarter. Capital World Investors now owns 15,318,948 shares of the biopharmaceutical company’s stock valued at $1,277,907,000 after buying an additional 3,380,000 shares during the period. Parnassus Investments CA boosted its stake in Gilead Sciences by 45.4% in the second quarter. Parnassus Investments CA now owns 8,460,484 shares of the biopharmaceutical company’s stock valued at $705,774,000 after buying an additional 2,640,284 shares during the period. Alliancebernstein L.P. boosted its stake in Gilead Sciences by 17.0% in the second quarter. Alliancebernstein L.P. now owns 13,346,714 shares of the biopharmaceutical company’s stock valued at $1,113,383,000 after buying an additional 1,942,138 shares during the period. Finally, Beacon Investment Advisory Services Inc. boosted its stake in Gilead Sciences by 9,951.3% in the second quarter. Beacon Investment Advisory Services Inc. now owns 1,653,145 shares of the biopharmaceutical company’s stock valued at $1,379,000 after buying an additional 1,636,698 shares during the period. 76.65% of the stock is currently owned by institutional investors.
Shares of Gilead Sciences Inc. (NASDAQ:GILD) traded up 0.19% during mid-day trading on Friday, hitting $75.44. The stock had a trading volume of 3,068,606 shares. Gilead Sciences Inc. has a 52-week low of $71.39 and a 52-week high of $108.31. The firm has a market cap of $99.39 billion, a PE ratio of 6.98 and a beta of 1.25. The firm has a 50 day moving average price of $74.56 and a 200 day moving average price of $80.20.
Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Tuesday, November 1st. The biopharmaceutical company reported $2.75 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $2.87 by $0.12. The business had revenue of $7.40 billion for the quarter, compared to analysts’ expectations of $7.47 billion. Gilead Sciences had a return on equity of 100.57% and a net margin of 47.74%. The firm’s quarterly revenue was down 9.6% on a year-over-year basis. During the same period last year, the firm earned $3.22 earnings per share. Equities analysts predict that Gilead Sciences Inc. will post $11.47 EPS for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Thursday, December 29th. Shareholders of record on Thursday, December 15th will be issued a dividend of $0.47 per share. This represents a $1.88 dividend on an annualized basis and a yield of 2.49%. The ex-dividend date of this dividend is Tuesday, December 13th. Gilead Sciences’s dividend payout ratio (DPR) is 17.44%.
Several research analysts have issued reports on the company. Jefferies Group raised their target price on Gilead Sciences from $91.00 to $93.00 and gave the stock a “buy” rating in a research report on Wednesday, October 5th. Piper Jaffray Cos. reissued a “buy” rating and issued a $108.00 target price on shares of Gilead Sciences in a research report on Monday, August 15th. Berenberg Bank assumed coverage on Gilead Sciences in a research report on Thursday, September 22nd. They issued a “buy” rating on the stock. Stifel Nicolaus assumed coverage on Gilead Sciences in a research report on Monday, November 14th. They issued a “buy” rating and a $100.00 target price on the stock. They noted that the move was a valuation call. Finally, Zacks Investment Research cut Gilead Sciences from a “hold” rating to a “sell” rating in a research report on Tuesday, September 6th. Ten research analysts have rated the stock with a hold rating, nineteen have issued a buy rating and two have issued a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $97.90.
In other Gilead Sciences news, Director John W. Madigan sold 105,000 shares of Gilead Sciences stock in a transaction dated Friday, November 18th. The stock was sold at an average price of $74.86, for a total transaction of $7,860,300.00. Following the completion of the sale, the director now directly owns 121,761 shares of the company’s stock, valued at approximately $9,115,028.46. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Gregg H. Alton sold 5,000 shares of Gilead Sciences stock in a transaction dated Thursday, September 22nd. The stock was sold at an average price of $81.84, for a total value of $409,200.00. Following the sale, the executive vice president now directly owns 132,964 shares of the company’s stock, valued at $10,881,773.76. The disclosure for this sale can be found here. Company insiders own 1.40% of the company’s stock.
Gilead Sciences Company Profile